NetworkNewsBreaks – Mustang Bio, Inc. (NASDAQ: MBIO) Closes $31.6M Public Offering
Mustang Bio (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, recently closed its underwritten public offering of 7,906,250 shares of common stock at a price of $4.00 each, which includes 1,031,250 additional shares in accordance with the full exercise of the over-allotment option. The company intends to use the gross proceeds of approximately $31.6 million toward the continued development of its product candidates, the possible development, in-license, acquisition and commercialization of other pharmaceutical products and for general corporate purposes.…







